Jinchuan Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jinchuan Wu has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Zhuoyue Song
Bioengineering Laboratory, Institute of Biological and Medical Engineering, Guangdong Academy of Sciences, Guangzhou, Guangdong, PR China
4 shared publications Qingxin Li
3 shared publicationsMingmei Xiao
South China Research Center for Acupuncture and Moxibustion, Guangzhou University of Chinese Medicine, Guangzhou 510006, Guangdong, PR China
2 shared publications- Qingxin Li
Guangdong Provincial Engineering Laboratory of Biomass High Value Utilization, Institute of Biological and Medical Engineering, Guangdong Academy of Sciences, Guangzhou, China
2 shared publications Shijie Li
South China Research Center for Acupuncture and Moxibustion, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, PR China
2 shared publications- Shijie Li
South China Research Center for Acupuncture and Moxibustion, Guangzhou University of Chinese Medicine, Guangzhou 510006, Guangdong, PR China
2 shared publications
Latest Publications
- Open Access
- 7 August 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (32) , e50021
From compounds to mechanism: unveiling the therapeutic action of Rudijinniuding on herpes zoster via integrated UPLC-Q/TOF-MS, network pharmacology, and molecular dynamics analyses
Rudijinniuding (RDJND), a proprietary formulation developed by Guangdong Provincial Hospital of Chinese Medicine, has demonstrated favorable anti-inflammatory and analgesic effects when applied in herpes zoster (HZ). However, its specific bioactive composition and underlying mechanisms remain unclear. The major constituents of RDJND were identified using ultra‑performance liquid chromatography with quadrupole/time‑of‑flight mass spectrometry. Network pharmacology was employed to screen for potential targets against HZ. Furthermore, molecular docking and molecular dynamics simulations were conducted to systematically elucidate the mechanism of action of RDJND against HZ. A total of 35 components were identified in RDJND, primarily alkaloids, phenolic acids, flavonoids, and coumarins. Network pharmacology analysis suggested that the effects of RDJND on HZ might involve the regulation of the phosphoinositide 3‑kinase/protein kinase B and mitogen‑activated protein kinase signaling pathways, as well as biological responses such as oxidative stress and responses to bacteria-derived molecules. Molecular docking and dynamics simulations further confirmed that the relevant complexes exhibited strong binding affinity and stability. This study clarified the bioactive composition of RDJND and its comprehensive pharmacological effects in the treatment of HZ through multi-target and multi-pathway mechanisms. These findings provide a theoretical basis for the clinical application of RDJND in HZ treatment and lay the groundwork for subsequent research and development efforts.
- 7 August 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (32) , e50021
Open AccessFrom compounds to mechanism: unveiling the therapeutic action of Rudijinniuding on herpes zoster via integrated UPLC-Q/TOF-MS, network pharmacology, and molecular dynamics analyses
Rudijinniuding (RDJND), a proprietary formulation developed by Guangdong Provincial Hospital of Chinese Medicine, has demonstrated favorable anti-inflammatory and analgesic effects when applied in herpes zoster (HZ). However, its specific bioactive composition and underlying mechanisms remain unclear. The major constituents of RDJND were identified using ultra‑performance liquid chromatography with quadrupole/time‑of‑flight mass spectrometry. Network pharmacology was employed to screen for potential targets against HZ. Furthermore, molecular docking and molecular dynamics simulations were conducted to systematically elucidate the mechanism of action of RDJND against HZ. A total of 35 components were identified in RDJND, primarily alkaloids, phenolic acids, flavonoids, and coumarins. Network pharmacology analysis suggested that the effects of RDJND on HZ might involve the regulation of the phosphoinositide 3‑kinase/protein kinase B and mitogen‑activated protein kinase signaling pathways, as well as biological responses such as oxidative stress and responses to bacteria-derived molecules. Molecular docking and dynamics simulations further confirmed that the relevant complexes exhibited strong binding affinity and stability. This study clarified the bioactive composition of RDJND and its comprehensive pharmacological effects in the treatment of HZ through multi-target and multi-pathway mechanisms. These findings provide a theoretical basis for the clinical application of RDJND in HZ treatment and lay the groundwork for subsequent research and development efforts.
- 10 October 2024
- Published by Oxford University Press (OUP) in Glycobiology
- Vol. 34 (12)
Bioinformatics-aided function exploration of GH29 fucosidases from human gut Parabacteroides
Gut microbes produce α-l-fucosidases critical for utilizing human milk oligosaccharides, mucosal and dietary glycans. Although gut Parabacteroides have garnered attention for their impact on host health and disease, their CAZymes remain poorly studied. CAZome analysis of eleven gut Parabacteroides type strains revealed their capacity to degrade mucin O-glycans. Their abundance of GH29 fucosidases caught our attention, and we predicted the functional profiles of 46 GH29 fucosidases using in silico approaches. Our findings showed diverse linkages specificities and species-specific distributions, with over half of GH29 enzymes functioning as α1,3/4 fucosidases, essential for acting on Lewis antigen epitopes of mucin O-glycans. We further enzymatically validated 4 novel GH29 sequences from poorly characterized groups. PgoldGH29A (cluster37 GH29BERT, GH29:75.1 CUPP) does not act on tested natural substrates. PgoldGH29B (cluster1 GH29BERT, GH29:84.1 CUPP) functions as a strict α1,3/4 fucosidase. PgoldGH29C (cluster14 GH29BERT, GH29:29.1 CUPP) displays unprecedented substrate specificity for α1,2/3/4 disaccharides. PgoldGH29D (cluster4 GH29BERT, GH29:6.2 CUPP) acts on α1,2/3/4/6 linkages similar to enzymes from GH29:6.1 CUPP but prefers disaccharides over trisaccharides. These results suggest that PgoldGH29B and PgoldGH29D can contribute to mucin O-glycan degradation via their α1,3/4 and α1,2 fucosidase activity, respectively, while the natural substrates of PgoldGH29A and PgoldGH29C may be irrelevant to host-glycans. These insights enhance our understanding of the ecological niches inhabited by gut Parabacteroides and may guide similar exploration in other intriguing gut microbial species.
- 10 October 2024
- Published by Oxford University Press (OUP) in Glycobiology
- Vol. 34 (12)
Bioinformatics-aided function exploration of GH29 fucosidases from human gut Parabacteroides
Gut microbes produce α-l-fucosidases critical for utilizing human milk oligosaccharides, mucosal and dietary glycans. Although gut Parabacteroides have garnered attention for their impact on host health and disease, their CAZymes remain poorly studied. CAZome analysis of eleven gut Parabacteroides type strains revealed their capacity to degrade mucin O-glycans. Their abundance of GH29 fucosidases caught our attention, and we predicted the functional profiles of 46 GH29 fucosidases using in silico approaches. Our findings showed diverse linkages specificities and species-specific distributions, with over half of GH29 enzymes functioning as α1,3/4 fucosidases, essential for acting on Lewis antigen epitopes of mucin O-glycans. We further enzymatically validated 4 novel GH29 sequences from poorly characterized groups. PgoldGH29A (cluster37 GH29BERT, GH29:75.1 CUPP) does not act on tested natural substrates. PgoldGH29B (cluster1 GH29BERT, GH29:84.1 CUPP) functions as a strict α1,3/4 fucosidase. PgoldGH29C (cluster14 GH29BERT, GH29:29.1 CUPP) displays unprecedented substrate specificity for α1,2/3/4 disaccharides. PgoldGH29D (cluster4 GH29BERT, GH29:6.2 CUPP) acts on α1,2/3/4/6 linkages similar to enzymes from GH29:6.1 CUPP but prefers disaccharides over trisaccharides. These results suggest that PgoldGH29B and PgoldGH29D can contribute to mucin O-glycan degradation via their α1,3/4 and α1,2 fucosidase activity, respectively, while the natural substrates of PgoldGH29A and PgoldGH29C may be irrelevant to host-glycans. These insights enhance our understanding of the ecological niches inhabited by gut Parabacteroides and may guide similar exploration in other intriguing gut microbial species.
- 20 April 2024
- Published by Springer Nature in Archives of Microbiology
- Vol. 206 (5) , 1-12
Characterization of Bacillus amyloliquefaciens PM415 as a potential bio-preserving probiotic
Animal feed is vulnerable to fungal infections, and the use of bio-preserving probiotics has received increasing attention. In contrast to Lactobacillus and Bifidobacteria spp., fewer Bacillus spp. have been recognized as antifungal probiotics. Therefore, our objective was to screen antifungal strains and provide more Bacillus candidates to bridge this gap. Here, we screened 56 bacterial strains for cyclic lipopeptide genes and conducted an antifungal assay with Aspergillus niger as a representative fungus. We found that a Bacillus strain Bacillus amyloliquefaciens PM415, isolated from pigeon manure, exhibited the highest fungal inhibition activity as demonstrated by the confrontation assay and morphological observation under scanning electron microscope (SEM). Preliminary safety assessment and probiotic characterization revealed its non-pathogenic feature and stress tolerance capability. Whole genome sequencing of Bacillus amyloliquefaciens PM415 revealed a genome size of 4.16 Mbp and 84 housekeeping genes thereof were used for phylogenetic analysis showing that it is most closely related to Bacillus amyloliquefaciens LFB112. The in silico analysis further supported its non-pathogenic feature at the genomic level and revealed potential biosynthetic gene clusters responsible for its antifungal property. RNA-seq analysis revealed genome-wide changes in transportation, amino acid metabolism, non-ribosomal peptides (NRPs) biosynthesis and glycan degradation during fungal antagonism. Our results suggest that Bacillus amyloliquefaciens PM415 is a safe and effective probiotic strain that can prevent fungal growth in animal feeds.
- 20 April 2024
- Published by Springer Nature in Archives of Microbiology
- Vol. 206 (5) , 1-12
Characterization of Bacillus amyloliquefaciens PM415 as a potential bio-preserving probiotic
Animal feed is vulnerable to fungal infections, and the use of bio-preserving probiotics has received increasing attention. In contrast to Lactobacillus and Bifidobacteria spp., fewer Bacillus spp. have been recognized as antifungal probiotics. Therefore, our objective was to screen antifungal strains and provide more Bacillus candidates to bridge this gap. Here, we screened 56 bacterial strains for cyclic lipopeptide genes and conducted an antifungal assay with Aspergillus niger as a representative fungus. We found that a Bacillus strain Bacillus amyloliquefaciens PM415, isolated from pigeon manure, exhibited the highest fungal inhibition activity as demonstrated by the confrontation assay and morphological observation under scanning electron microscope (SEM). Preliminary safety assessment and probiotic characterization revealed its non-pathogenic feature and stress tolerance capability. Whole genome sequencing of Bacillus amyloliquefaciens PM415 revealed a genome size of 4.16 Mbp and 84 housekeeping genes thereof were used for phylogenetic analysis showing that it is most closely related to Bacillus amyloliquefaciens LFB112. The in silico analysis further supported its non-pathogenic feature at the genomic level and revealed potential biosynthetic gene clusters responsible for its antifungal property. RNA-seq analysis revealed genome-wide changes in transportation, amino acid metabolism, non-ribosomal peptides (NRPs) biosynthesis and glycan degradation during fungal antagonism. Our results suggest that Bacillus amyloliquefaciens PM415 is a safe and effective probiotic strain that can prevent fungal growth in animal feeds.
- Open Access
- 12 March 2024
- Published by MDPI AG in Nanomaterials
- Vol. 14 (6) , 512
The Pd (II) Reduction Mechanisms in Bacillus megaterium Y-4 Revealed by Proteomic Analysis
Many studies have been conducted on the microbial reduction of Pd (II) to palladium nanoparticles (Pd-NPs) due to the environmental friendliness, low cost, and the decreased toxicity of Pd (II) ions. In this study, we investigate the reduction mechanism of Pd (II) by Bacillus megaterium Y-4 through proteomics. The data are available via ProteomeXchange with identifier PXD049711. Our results revealed that B. megaterium Y-4 may use the endogenous electron donor (NAD(P)H) generated by nirB, tdh, and fabG and reductase to reduce Pd (II) to Pd-NPs. The expression levels of fabG, tdh, gudB, and rocG that generate NAD(P)H were further increased, and the number of reduced Pd-NPs was further increased with the exogenous electron donor sodium formate. Endogenous electron mediators such as quinones and flavins in B. megaterium Y-4 can further enhance Pd (II) reduction. The findings provided invaluable information regarding the reduction mechanism of Pd (II) by B. megaterium Y-4 at the proteome level.
- 12 March 2024
- Published by MDPI AG in Nanomaterials
- Vol. 14 (6) , 512
Open AccessThe Pd (II) Reduction Mechanisms in Bacillus megaterium Y-4 Revealed by Proteomic Analysis
Many studies have been conducted on the microbial reduction of Pd (II) to palladium nanoparticles (Pd-NPs) due to the environmental friendliness, low cost, and the decreased toxicity of Pd (II) ions. In this study, we investigate the reduction mechanism of Pd (II) by Bacillus megaterium Y-4 through proteomics. The data are available via ProteomeXchange with identifier PXD049711. Our results revealed that B. megaterium Y-4 may use the endogenous electron donor (NAD(P)H) generated by nirB, tdh, and fabG and reductase to reduce Pd (II) to Pd-NPs. The expression levels of fabG, tdh, gudB, and rocG that generate NAD(P)H were further increased, and the number of reduced Pd-NPs was further increased with the exogenous electron donor sodium formate. Endogenous electron mediators such as quinones and flavins in B. megaterium Y-4 can further enhance Pd (II) reduction. The findings provided invaluable information regarding the reduction mechanism of Pd (II) by B. megaterium Y-4 at the proteome level.
- 27 September 2023
- Published by Elsevier in Journal of Bioscience and Bioengineering
- Vol. 136 (5) , 383-390
Efficient removal of purine compounds from solutions via biomass carbons derived from pomelo peel
- 27 September 2023
- Published by Elsevier in Journal of Bioscience and Bioengineering
- Vol. 136 (5) , 383-390
Efficient removal of purine compounds from solutions via biomass carbons derived from pomelo peel
- 29 June 2023
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 317, 116872
Advantage effect of Dalbergia pinnata on wound healing and scar formation of burns
- 29 June 2023
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 317, 116872
Advantage effect of Dalbergia pinnata on wound healing and scar formation of burns
- 28 February 2023
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 235, 123853
Polysaccharides from Ostrea rivularis rebuild the balance of gut microbiota to ameliorate non-alcoholic fatty liver disease in ApoE−/− mice
- 28 February 2023
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 235, 123853
Polysaccharides from Ostrea rivularis rebuild the balance of gut microbiota to ameliorate non-alcoholic fatty liver disease in ApoE−/− mice